ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
